Immuron Ltd (NASDAQ:IMRN, ASX:IMC) CEO Steve Lydeamore speaks with Proactive following news the company has achieved record monthly sales of its over-the-counter gastrointestinal supplement Travelan®. For August, the company registered Australian sales amounting to A$1.18 million, representing a staggering 7,984% increase compared to A$14,581 in August 2022. The monumental sales boost partially mirrors the clearance of a three-month backlog of orders, which had accumulated during a period awaiting Good Manufacturing Practice (GMP) clearance from the TGA.
Immuron hails record monthly sales of Travelan
